

**Vitronectin (VTN): A Novel Diagnostic And
Prognostic Marker for Hepatocellular
Carcinoma (HCC) On Top Of Chronic Hepatitis
C Virus Related Diseases**

A Thesis

Submitted for partial fulfillment of Master degree
in Internal Medicine

By

Hamed Saad Badawy Saad

M.B.B.Ch, Faculty of Medicine, Mansoura University
Resident of Internal Medicine at Mahalla Hepatology Teaching Hospital

Under Supervision of

Prof. Dr. Amal Shawky Mohamed Bakir

Professor of Internal Medicine, Hepatology and Gastroenterology
Faculty of Medicine, Ain Shams University

Dr. Hesham Hamdy Al-Kilany

Assistant Professor of Internal Medicine, Hepatology and Gastroenterology
Faculty of Medicine, Ain Shams University

Dr. Ramy Samir Ghait

Lecturer of Internal Medicine, Hepatology and Gastroenterology
Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسببائك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgments

*First and foremost, I feel always indebted to **Allah**, the **Most Beneficent** and **Merciful** who gave me the strength to accomplish this work,*

*My deepest gratitude to my supervisor, **Prof. Dr. Amal Shawky Mohamed Bakir**, Professor of Internal Medicine, Hepatology and Gastroenterology, Faculty of Medicine, Ain Shams University, for her valuable guidance and expert supervision, in addition to her great deal of support and encouragement. I really have the honor to complete this work under her supervision.*

*I would like to express my great and deep appreciation and thanks to **Dr. Hesham Hamdy Al-Kilany**, Assistant Professor of Internal Medicine, Hepatology And Gastroenterology, Faculty of Medicine, Ain Shams University, for his meticulous supervision, and his patience in reviewing and correcting this work,*

*I must express my deepest thanks to **Dr. Ramy Samir Ghait**, Lecturer of Internal Medicine, Hepatology and Gastroenterology, Faculty of Medicine, Ain Shams University, for guiding me throughout this work and for granting me much of his time. I greatly appreciate his efforts.*

*Special thanks to my **Parents**, my **Wife and Kids** and all my **Family** members for their continuous encouragement, enduring me and standing by me.*

 **Hamed Saad Badawy Saad**

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations.....	i
List of Tables.....	vi
List of Figures	viii
Introduction	1
Aim of the Work.....	4
Review of Literature	
Hepatitis C virus.....	5
Liver Cirrhosis	34
Vitronectin.....	55
Hepatocellular carcinoma	72
Patients and Methods.....	97
Results.....	103
Discussion	123
Summary	134
Conclusions	139
References	142
Arabic Summary	—

List of Abbreviations

Abbr.	Full-term
18F-FDG	: 18F-fluorodeoxyglucose
AAR	: Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) ratio
AASLD	: American Association for the Study of Liver Disease
AFP	: Alpha-Fetoprotein
AFU	: α -L-fucosidase
ALP	: Alkaline phosphatase
ALT	: Alanine aminotransferase
APHE	: Arterial phase hyperenhancement
AST	: Aspartate aminotransferase
AUC	: Area under the curve.
BCLC	: Barcelona Clinic Liver Cancer staging system
CBC	: Complete blood count
CC	: Cholangiocarcinoma
CLIP	: Cancer of the liver Italian program
CT	: Computerized Tomography
CUPI	: Chinese University Prognostic Index
DAAs	: Direct-acting antiviral agents
DAC	: Daclatasvir
DCP	: Des-gamma-carboxy prothrombin
DNA	: Deoxyribonucleic acid
DWI	: Diffusion-weighted imaging

EASL	: European Association for the Study of the Liver diseases
ECOG	: Eastern Cooperative Oncology Group
EGF	: Epithelial growth factor
ELISA	: enzyme-linked immunosorbent assays
FDA	: Food and Drug Administration
Genotype	: GT
GP-73	: Golgi protein-73
GPC-3	: Glypican-3
HB	: Hemoglobin
HBs-Ag	: Hepatitis B virus surface Antigen
HBV	: Hepatitis B virus
HCC	: Hepatocellular carcinoma
HCV	: Hepatitis C virus
HIV	: Human Immunodeficiency Virus
HKLC	: Hong-Kong Liver Cancer
HRS	: Hepatorenal syndrome
IFN-free	: Interferon -free
IgG	: Immunoglobulin G
INR	: International Normalized Ratio
IU per ml	: International Units Per Millilitre
JIS	: Japan Integrated Staging
KW	: Kruskal Wallis test
LED	: Ledipasvir
LT	: Liver transplantation
MELD	: Model for End-Stage Liver Disease
miRNAs	: MicroRNAs

MRI	: Magnetic Resonance Imaging
MWA	: Microwave ablation
NAFLD	: Non-alcoholic fatty liver disease
NCCVH	: National Committee for Control of Viral Hepatitis
NK	: Natural killer cells
NPV	: Negative predictive value.
χ^2	: Chi-Square test
NS3/4A PIs	: Nonstructural 3/4A Protease Inhibitors
NS5A	: Nonstructural 5A Polymerase Inhibitors
NS5B NNPIs	: Nonstructural 5B NON nucleoside Polymerase Inhibitors
NS5B NPIs	: Nonstructural 5B nucleoside Polymerase Inhibitors
NSAIDs	: Non-steroidal anti-inflammatory drugs
OMB	: Ombitasvir
ORF	: Open reading frame
PAI-1	: Plasminogen activator inhibitor-1
PAR	: Paritaprevir
PBC	: Primary Biliary Cholangitis
PCR	: Polymerase Chain Reaction
PD-1	: Programmed cell death protein-1
PDFGRα	: Platelet-derived growth factor receptor α
PEG-IFN	: Pegylated interferon
PEI	: Percutaneous ethanol injection
PET	: Positron emission tomography
PIVKA	: Prothrombin induced by vitamin K absence
PLT	: Platelets
PPV	: Positive predictive value

PSC	: Primary Sclerosing Cholangitis
PVT	: Portal vein thrombosis
RASs	: Resistance-associated substitutions
RBV	: Ribavirin
RdRp	: RNA-dependent RNA polymerase
RFA	: Radiofrequency ablation
RNA	: Ribonucleic acid
ROC	: Receiver Operator Characteristic
SBP	: Spontaneous bacterial peritonitis
SCCA	: Squamous cell carcinoma antigen
SIM	: Simeprevir
SIRT	: Selective internal radiation therapy
SOF	: Sofosbuvir
SPSS	: Statistical Package for Social Sciences
SVR	: Sustained Virological Response
TACE	: Transarterial chemoembolization
TERC	: Telomerase RNA component
TERT	: Telomerase reverse transcriptase
TGF-b1	: Transforming Growth Factor b1
TIPS	: Transjugular intrahepatic portosystemic shunt
TKI	: Tyrosine-kinase inhibitor
TTV	: Total tumor volume
UCSF	: University of California, San Francisco
UK	: United Kingdom
US	: The United States
US	: Ultrasound

UTRs	: Untranslated regions
VEGF	: Vascular endothelial growth factor
VEGFR	: Vascular endothelial growth factor receptor
VTN or VN	: Vitronectin
WBCs	: White Blood Corpuscles
WHO	: World Health Organization
Y90	: Yttrium 90

List of Tables

Table No.	Title	Page No.
Table (1):	Classification of new antiviral drugs	23
Table (2):	Recommended regimens and durations (weeks) for patients without cirrhosis who have never been treated, according to HCV genotype	30
Table (3):	Recommended regimens and durations (weeks) for patients with compensated cirrhosis who have never been treated, according to HCV genotype	31
Table (4):	Summary of product and dosing information for the direct-acting antivirals approved by the US Food and Drug Administration and European Medicines Agency	32
Table (5):	Child Pugh Score	52
Table (6):	Geographical distribution of main risk factors for primary liver cancer world-wide	73
Table (7):	Comparison of the demographic data within the study groups	103
Table (8):	Comparison of the comorbidities and smoking within the study groups	105
Table (9):	Comparison of the laboratory investigations within the study groups	106
Table (10):	Comparison of the levels of AFP and vitronectin before treatment in the four study groups	110

Table (11): Comparison of the demographic data within the study groups.....	112
Table (12): Comparison of the levels of HCV PCR.....	113
Table (13): Comparison of the Child PUGH score in the cases in cirrhosis and HCC groups	114
Table (14): Tumour criteria according to BCLC, tumour size and number of lesions	115
Table (15): Serum level of AFP and vitronectin level in group IV before and after treatment	118
Table (16): Prediction of ability of Vitronectin to differentiate between normal & HCV +ve cases.....	119
Table (17): Prediction of ability of Vitronectin to differentiate between HCV +ve cases & cirrhosis.....	120
Table (18): Prediction of ability of Vitronectin to differentiate between cirrhosis & HCC.....	121
Table (19): Analysis of the interventional methods in cases with HCC.....	122

List of Figures

Figure No.	Title	Page No.
Figure (1):	Global distribution of HCV genotypes	7
Figure (2):	HCV prevalence.....	8
Figure (3):	Timeline of hepatitis C virus prevalence in Egypt among adults	8
Figure (4):	HCV life cycle	11
Figure (5):	Hepatitis C virus (HCV) genome and potential drug discovery targets.....	24
Figure (6):	Journey of chronic hepatitis C virus (HCV) patients through the Egyptian HCV model of care.	33
Figure (7):	Causes of liver Cirrhosis.....	36
Figure (8):	Evolution of liver resolution.	37
Figure (9):	Clinical spectrum of cirrhosis	42
Figure (10):	The new theory on the development of complications and organ failure/s in patients with cirrhosis (adapted from Ref. 5).....	45
Figure (11):	The sites of portosystemic communication.....	46
Figure (12):	A, illustration of Gastro-oesophageal varices arise from the left gastric vein (coronary vein) and drain into the azygous vein. B, fluoroscopic spot image demonstrating the appearance of these varices	47

Figure (13):	(A) Grade I oesophageal varices.....	48
Figure (14):	Upper panel: localization of the binding domains of vitronectin towards various ligands	57
Figure (15):	Schematic presentation of possible regulatory assignments of vitronectin.....	60
Figure (16):	Major biological functions in which vitronectin has been implicated.	61
Figure (17):	Vitronectin expression is increased in HCC.	70
Figure (18):	Vitronectin expression is increased in CHM.....	71
Figure (19):	Mechanism of hepatic encephalopathy.....	77
Figure (20):	Diagnostic algorithm for the study of a nodule detected in the screening program	78
Figure (21):	Modified BCLC staging system and treatment strategy	89
Figure (22):	Multidetector CT device	100
Figure (23):	Distribution of age among the study groups.....	104
Figure (24):	Distribution of gender among the study groups.....	104
Figure (25):	Comparison of the comorbidities and smoking within the study groups.....	105
Figure (26):	Mean of Hemoglobin in different study groups.....	107

Figure (27):	Median of Platelets in different study groups.....	107
Figure (28):	Median of white blood cells in different study groups	107
Figure (29):	Median of Creatinine in different study groups.....	108
Figure (30):	Mean of INR in different study groups....	108
Figure (31):	Mean of Albumin in different study groups.....	108
Figure (32):	Median of Total bilirubin and Direct bilirubin in different study groups	109
Figure (33):	Median of ALT and AST in different study groups	109
Figure (34):	Median of AFP in different study groups before treatment	111
Figure (35):	Median of Vitronectin in different study groups before treatment.....	111
Figure (36):	Comparison of the Child Pugh score in the cases in cirrhosis and HCC groups	114
Figure (37):	Tumour criteria according to BCLC.....	116
Figure (38):	Tumour criteria according to number of lesions	116
Figure (39):	Tumour criteria according to tumour size	117
Figure (40):	Prediction of ability of Vitronectin to differentiate between normal & HCV +ve cases by ROC curve	119

Figure (41):	Prediction of ability of Vitronectin to differentiate between HCV +ve cases & cirrhosis by ROC curve.....	120
Figure (42):	Prediction of ability of Vitronectin to differentiate between cirrhosis & HCC by ROC curve	121
Figure (43):	Analysis of the interventional methods in cases with HCC.....	122